Table 11B:
Fibroid-Related Symptom Reduction With Complete or Near-Complete MRgHIFU Ablation Protocols
| Country, Author, Year | Study Size, N | Symptom Measures | Symptom Reduction at Follow-Up Points | |||
|---|---|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | |||
| Australia, Dobrotwir A et al, 2012 (94) | 100 | UFS-QOL (SSS) Mean ± SD | 59 ± 21 | 37 ± 22 P < 0.001 | 34 ± 22 P < 0.001 | 29 ± 17 P < 0.001 |
| Germany, Trumm C et al, 2013 (91) | 115 | UFS-QOL (SSS) Median (IQR) | 63 (38–73) | NR | 38 (25–44) | |
| India, Desai S et al, 2012 (95) | 50 | UFS-QOL (SSS) Mean ± SD | 57 ± 5 | NR | 29 ± 6 P < 0.001 | |
| India, Himabindu Y et al, 2014 (105) | 32 | UFS-QOL (SSS) Mean ± SD | 68 ± 7 | 30 ± 5 P < 0.01 | 27 ± 6 P < 0.01 | |
| Korea, Park M et al, 2014 (82) | 79 | UFS-QOL (SSS) Mean ± SD (range) | 43 ± 16 (13–81) | 28 ± 15 (6–59) P < 0.001 | ||
| Japan, Mikami et al 2008 (90) | 48 | Self-reported symptom improvement | NR | See summary in text | See summary in text | |
| United States, Gorny K et al 2011 (97) | 150 | See summary in text | See summary in text | See summary in text | ||
Abbreviations: IQR, inter-quartile range; MRgHIFU, magnetic resonance-guided high-intensity focused ultrasound; NR, not reported; SD, standard deviation; SSS; symptom severity score; UFS-QOL, Uterine Fibroid Symptom and Quality of Life questionnaire.